HK Innoen Presents Latest Research on GERD New Drug 'K-CAB' at European Conference

Helicobacter Eradication Therapy and Excellence in Nighttime Heartburn Management Highlighted

A research officer from the European Society of Gastroenterology is presenting the research results of K-CAB.
[Photo by HK Innoen]

[Asia Economy Reporter Lee Gwan-joo] HK inno.N recently announced on the 26th that it participated consecutively in the European Helicobacter Study Group (EHMSG 2022) and the United European Gastroenterology Week (UEGW 2022) to present the latest research results on the P-CAB class gastroesophageal reflux disease (GERD) new drug 'K-CAB' (generic name: Tegoprazan).

At the European Helicobacter Study Group, Professor Jeong Jun-won of the Department of Gastroenterology at Gachon University Gil Medical Center revealed the results comparing the success rates of bismuth-containing quadruple therapy for Helicobacter pylori eradication.

As a result of eradication therapy using a quadruple regimen including bismuth based on either Tegoprazan or PPI-class drugs, the Tegoprazan-based quadruple therapy group showed a 90.2% eradication rate, while the PPI-based quadruple therapy group showed 82.4%, demonstrating that the Tegoprazan-based quadruple therapy had a higher therapeutic effect. Currently, the Korean Society of Upper Gastrointestinal and Helicobacter recommends using four drugs?acid secretion inhibitors, bismuth, metronidazole, and tetracycline?as one of the first-line eradication therapies for Helicobacter pylori.

Additionally, at the European Gastroenterology Congress, results from a phase 3 maintenance therapy study and a phase 4 study related to nighttime heartburn and sleep disturbances were presented. The phase 3 maintenance therapy clinical trial was conducted on 351 patients in Korea confirmed to have healed erosive GERD. To prevent recurrence of GERD, patients took K-CAB tablets 25 mg for up to six months, confirming not only the maintenance of therapeutic effect but also safety during long-term use. In particular, the maintenance therapy in patients with moderate or higher severity showed superior effects compared to the PPI administration group, and similar effects were observed regardless of specific genotypes (CYP2C19), according to the company.

HK Innoen 'K-CAB Tablet' [Photo by HK Innoen]

A phase 4 clinical presentation related to nighttime heartburn and sleep disturbances also followed. Researchers examined the speed at which nighttime heartburn disappeared in groups taking Tegoprazan and PPI for two weeks, confirming that Tegoprazan, a P-CAB class drug, relieved nighttime heartburn faster than PPI-class drugs. The researchers concluded that Tegoprazan not only rapidly suppresses gastric acid secretion but also has a long duration of action, which can improve sleep quality by preventing awakening due to heartburn during sleep.

Song Geun-seok, Executive Director of R&D at HK inno.N, said, "K-CAB is conducting various differentiated clinical studies as well as clinical research aimed at expanding indications, and a paper on maintenance therapy will soon be published in an SCI-level international journal. Starting with the presentation of the latest research results on K-CAB at major European conferences, we will accelerate global expansion."

K-CAB has indications for erosive GERD, non-erosive GERD, gastric ulcers, antibiotic combination therapy for Helicobacter pylori eradication, and maintenance therapy after erosive GERD treatment. It has been launched in two formulations: tablets and orally disintegrating tablets, and the company is preparing to launch K-CAB tablets 25 mg, which is half the dose of K-CAB tablets 50 mg, next year.

This content was produced with the assistance of AI translation services.